News
A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to ...
Tricare officials said the Defense Health Agency is eliminating coverage for its Tricare for Life beneficiaries and others to ...
New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...
Williams joins a growing list of celebrities who have publicly shared their use of weight loss medications, including Oprah Winfrey, Whoopi Goldberg, singer Meghan Trainor and basketball legend ...
Sales of Wegovy weight loss jabs soar 27-fold after rival Mounjaro ramps up price in UK - CheqUp said it had experienced a ...
As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback